Study shows how prostate tumors rewire metabolism to resist therapy - News-Medical

Prostate tumors have been found to rewire their metabolism to resist hormone therapy. The tumors hijack amino acid metabolism, specifically isoleucine and valine, to alter cholesterol metabolism. This metabolic rewiring allows the cancer to progress despite treatment. The study, published in Nature, identifies a specific mechanism: isoleucine and valine promote cancer progression through propionyl-CoA-mediated cholesterol metabolism.

This finding suggests that targeting these amino acids or their metabolic pathways could potentially overcome treatment resistance. However, the practical implications of this research are not yet clear. The study does not specify how this new understanding might translate into clinical practice. Nor does it address whether other types of cancer might use similar metabolic strategies to resist therapy.

The study does not yet address how widespread this metabolic adaptation might be among prostate cancer patients. Nor does it specify whether the findings apply to all stages of prostate cancer. The study also does not address whether other therapies might be affected by this metabolic rewiring.